Narlumosbart with SBRT shows promise in NSCLC with bone metastases in new Phase II trial
A Phase II trial is investigating narlumosbart, RANKL-targeting mAb, combined with SBRT and first-line chemotherapy/immunotherapy in NSCLC patients with bone metastases.